Abstract
Clinical perspective on the impact of coronavirus (COVID-19) pandemic on individuals with glucose -6- phosphate dehydrogenase deficiency (G6PD)
Highlights
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme that catalyzes the initial and the rate-limiting reaction step in the pentose phosphate pathway (HMP) which converts NADP into NADPH
NADPH is required for the generation of reduced glutathione an important antioxidant used to protects red blood cells from oxidative damage.Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy worldwide, affecting an estimated 400 million people and exists in concentrated regions in Africa, the Middle East, and Southeast Asia, and about one in 10 African-American males are affected in the United States [1,2,3]
G6PD-deficient patients may develop acute hemolytic anemia after exposure to oxidative stress because the HMP shunt is their only source of NADPH
Summary
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme that catalyzes the initial and the rate-limiting reaction step in the pentose phosphate pathway (HMP) which converts NADP into NADPH. Clinical perspective on the impact of coronavirus (COVID-19) pandemic on individuals with glucose -6phosphate dehydrogenase deficiency (G6PD)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
